TY - JOUR
AB - Altered glucose metabolism is an important characteristic of cancer cells, which is referred to as Warburg effect or aerobic glycolysis. Ewing sarcoma (EWS) is a highly malignant tumor that occurs in children and adolescents. However, the functions of aerobic glycolysis in EWS remain to be elucidated. The present study identified a transcription factor, E2F transcription factor 1 (E2F1), as a new regulator of cancer the aerobic glycolysis and progression in EWS. The present study showed that E2F1 modulated aerobic glycolysis in EWS cells by effecting glucose uptake, lactate production and ATP generation. Altered E2F1 expression increased or decreased cell viability and invasion in EWS. Mechanistically, the results demonstrated that E2F1 may promote the Warburg effect and cancer progression in EWS via upregulating enolase 2 expression. Generally, these findings indicated that E2F1 involvement in the progression of EWS and could serve as a clinical therapeutic target in EWS.
AD - Department of Orthopedics, Wuhan Hanyang Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430050, P.R. China
Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Medical Examination Center, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
AU - Jiang,Xianyong
AU - Chen,Zhen
AU - Zhu,Junping
AU - Han,Jun
AU - You,Gaoliang
AU - Li,Yonghong
AU - Liu,Tiancheng
AU - Ye,Heng
DA - 2022/07/01
DO - 10.3892/mmr.2022.12753
IS - 1
JO - Mol Med Rep
KW - E2F transcription factor 1
aerobic glycolysis
cancer progression
Ewing sarcoma
PY - 2022
SN - 1791-2997
1791-3004
SP - 237
ST - E2F1 promotes Warburg effect and cancer progression via upregulating ENO2 expression in Ewing sarcoma
T2 - Molecular Medicine Reports
TI - E2F1 promotes Warburg effect and cancer progression via upregulating ENO2 expression in Ewing sarcoma
UR - https://doi.org/10.3892/mmr.2022.12753
VL - 26
ER -